This fall, Open Therapeutics (OT) expects to debut an elegant platform that will allow scientists and researchers to collaborate on all aspects of Bioresearch and development. University researchers who have conducted exhaustive research on treatments for disease, yet find themselves stifled by isolation, will be able to team up with other like-minded researchers to share data and results. When breakthroughs are reached, each researcher will be able to produce papers that complement the research of others, all the while receiving appropriate recognition for their own work. The beneficiaries will not only be scientists, but also the public, which has struggled for years with the high cost of treatments and drugs.
Open Therapeutics will bring together pools of university researchers, corporations, non-profits, entrepreneurs, and inventors who may be focusing on the same bio problem.
Scott Wager (Follow Him on Twitter @WagersScott) writes in his insightful article 20 Benefits of Collaboration As a Researcher You Cannot Afford to Ignore that it all begins with the benefits of collaboration….
- Higher impact publications: There is a direct correlation between the number of authors and impact factor. Not much more needs to be said. This is probably more a reflection of the fact that good science requires the combined efforts of many good scientists.
- Knowledge of what others are doing: You can read papers or look at patent filings, yet there is no better way to know what others are doing than talking to them. In industry and in research it is always best to be where everyone else is.
- Early adopters: Your collaboration partners are almost by definition your early adopters for your novel approach, new technology, or new hypothesis. You can also think about it as the best way to foster paradigm shift. It all begins with a dedicated group of core believers.
- Impressing investors: That what you are doing is accepted by a group of leaders in the field is no better argument for convincing investors. This is also true for funding agencies.
All researchers will now have access to a web portal service that reduces the cost and risk of developing and deploying therapeutics. By stimulating an economies of scale model and micro-pharma indigenous industries, the global population should experience lower prices and greater availability of life-saving drugs.